Literature DB >> 11395395

Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11.

J C Fournet1, C Mayaud, P de Lonlay, M S Gross-Morand, V Verkarre, M Castanet, M Devillers, J Rahier, F Brunelle, J J Robert, C Nihoul-Fékété, J M Saudubray, C Junien.   

Abstract

Congenital hyperinsulinism (CHI), previously named persistent hyperinsulinemic hypoglycemia of infancy, is characterized by profound hypoglycemia because of excessive insulin secretion. CHI presents as two different morphological forms: a diffuse form with functional abnormality of islets throughout the pancreas and a focal form with focal islet cell adenomatous hyperplasia, which can be cured by partial pancreatectomy. Recently, we have shown that focal adenomatous hyperplasia involves the specific loss of the maternal 11p15 region and a constitutional mutation of a paternally inherited allele of the gene encoding the regulating subunit of the K(+)(ATP) channel, the sulfonylurea receptor (ABCC8 or SUR1). In the present study on a large series of 31 patients, describing both morphological features and molecular data, we report that 61% of cases (19 out of 31) carried a paternally inherited mutation not only in the ABCC8 gene as previously described but also in the second gene encoding the K(+)(ATP) channel, the inward rectifying potassium channel (KCNJ11 or KIR6.2), in 15 cases and 4 cases, respectively. Moreover our results are consistent with the presence of a duplicated paternal 11p15 allele probably because of mitotic recombination or reduplication of the paternal chromosome after somatic loss of the maternal chromosome. In agreement with the loss of the maternal chromosome, the level of expression of a maternally expressed tumor suppressor gene, H19, was greatly reduced compared to the level of expression of the paternally expressed growth promoter gene, IGF2. The expression of IGF2 was on average only moderately increased. Thus, focal forms of CHI can be considered to be a recessive somatic disease, associating an imbalance in the expression of imprinted genes in the 11p15.5 region to a somatic reduction to homozygosity of an ABCC8- or KCNJ11-recessive mutation. The former is responsible for the abnormal growth rate, as in embryonic tumors, whereas the latter leads to unregulated secretion of insulin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395395      PMCID: PMC1891997          DOI: 10.1016/S0002-9440(10)64689-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

Review 1.  Hyperinsulinism in infants and children.

Authors:  C A Stanley
Journal:  Pediatr Clin North Am       Date:  1997-04       Impact factor: 3.278

2.  Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy.

Authors:  P de Lonlay; J C Fournet; J Rahier; M S Gross-Morand; F Poggi-Travert; V Foussier; J P Bonnefont; M C Brusset; F Brunelle; J J Robert; C Nihoul-Fékété; J M Saudubray; C Junien
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM.

Authors:  H Inoue; J Ferrer; M Warren-Perry; Y Zhang; H Millns; R C Turner; S C Elbein; C L Hampe; B K Suarez; N Inagaki; S Seino; M A Permutt
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

4.  Cure of hypoglycemic hyperinsulinism by enucleation of a focal islet cell adenomatous hyperplasia.

Authors:  R D Craver; C B Hill
Journal:  J Pediatr Surg       Date:  1997-10       Impact factor: 2.545

5.  Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy.

Authors:  P Thomas; Y Ye; E Lightner
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

6.  A syndrome of congenital hyperinsulinism and hyperammonemia.

Authors:  S A Weinzimer; C A Stanley; G T Berry; M Yudkoff; M Tuchman; P S Thornton
Journal:  J Pediatr       Date:  1997-04       Impact factor: 4.406

7.  An autosomal dominant form of familial persistent hyperinsulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus.

Authors:  A Kukuvitis; C Deal; L Arbour; C Polychronakos
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

8.  Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis.

Authors:  H Cui; F Hedborg; L He; A Nordenskjöld; B Sandstedt; S Pfeifer-Ohlsson; R Ohlsson
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

9.  A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism.

Authors:  A Nestorowicz; N Inagaki; T Gonoi; K P Schoor; B A Wilson; B Glaser; H Landau; C A Stanley; P S Thornton; S Seino; M A Permutt
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

10.  Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas.

Authors:  C Béroud; J C Fournet; C Jeanpierre; D Droz; R Bouvier; D Froger; Y Chrétien; J M Maréchal; J Weissenbach; C Junien
Journal:  Genes Chromosomes Cancer       Date:  1996-12       Impact factor: 5.006

View more
  28 in total

Review 1.  Role of 18F-DOPA PET/CT imaging in congenital hyperinsulinism.

Authors:  Dunia Ismail; Khalid Hussain
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

Review 2.  Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia.

Authors:  Kate Bennett; Chela James; Khalid Hussain
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

Review 3.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Transient receptor potential channelopathies.

Authors:  Bernd Nilius; Grzegorz Owsianik
Journal:  Pflugers Arch       Date:  2010-02-04       Impact factor: 3.657

Review 5.  Benign Tumors and Tumorlike Lesions of the Pancreas.

Authors:  Olca Basturk; Gokce Askan
Journal:  Surg Pathol Clin       Date:  2016-12

Review 6.  Diabetes mellitus--advances and challenges in human β-cell proliferation.

Authors:  Peng Wang; Nathalie M Fiaschi-Taesch; Rupangi C Vasavada; Donald K Scott; Adolfo García-Ocaña; Andrew F Stewart
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 7.  Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders.

Authors:  Yi Quan; Andrew Barszczyk; Zhong-ping Feng; Hong-shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

8.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

9.  A mutation (R826W) in nucleotide-binding domain 1 of ABCC8 reduces ATPase activity and causes transient neonatal diabetes.

Authors:  Heidi de Wet; Peter Proks; Mathilde Lafond; Jussi Aittoniemi; Mark S P Sansom; Sarah E Flanagan; Ewan R Pearson; Andrew T Hattersley; Frances M Ashcroft
Journal:  EMBO Rep       Date:  2008-05-23       Impact factor: 8.807

10.  The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children.

Authors:  Maria-João Ribeiro; Nathalie Boddaert; Christine Bellanné-Chantelot; Sandrine Bourgeois; Vassili Valayannopoulos; Thierry Delzescaux; Francis Jaubert; Claire Nihoul-Fékété; Francis Brunelle; Pascale De Lonlay
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.